DarioHealth Corp. (NASDAQ: DRIO) announced that a review by the Managed Care Services Team of Aon plc supports estimated annual healthcare cost reductions of 2.5% to 7.2% for populations using its AI-powered chronic condition management services. The review, based on data and studies provided or identified by DarioHealth, concluded that the evidence supports meaningful clinical and financial outcomes across cardiometabolic, musculoskeletal, and behavioral health conditions.
For a representative population of 20,000 covered lives, the estimated savings translate to approximately $3.8 million to $10.8 million annually. Aon also noted that management of multiple conditions and access to physicians—excluded from the initial calculations—could contribute an additional 1.6 to 2.8 percentage points in savings. The review evaluated 17 studies, including independently conducted and company-sponsored research, and found consistent reported improvements across clinical, behavioral, healthcare utilization, and cost measures.
However, Aon did not independently verify the underlying data or audit the studies, and its findings do not guarantee future savings or outcomes for individual customers. The company’s integrated platform combines connected devices, personalized member engagement, AI-driven insights, and provider-backed clinical care to support people with conditions such as diabetes, hypertension, weight management, musculoskeletal issues, and behavioral health needs. Powered by more than 13 billion proprietary longitudinal healthcare data points collected over more than a decade, Dario’s AI platform personalizes care at the individual member level.
The announcement matters because it provides third-party validation of DarioHealth’s potential to reduce healthcare costs, a critical consideration for health plans, health systems, and employers seeking to address rising chronic disease expenses. If the estimated savings hold true, DarioHealth could become a more attractive partner for payers and providers aiming to improve outcomes while lowering costs. The full press release is available at https://ibn.fm/IFvLH. For ongoing updates on DRIO, visit the company’s newsroom at https://ibn.fm/DRIO.
The announcement was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, and a full array of tailored corporate communications solutions. The platform aims to help private and public companies reach investors, influencers, consumers, and journalists.
